908 Devices Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 8, 2024. This is an annual filing, and the supplied text does not provide standalone fourth-quarter results. The company develops handheld and desktop instruments for point-of-need chemical and biochemical analysis, serving government and forensics customers as well as life sciences and bioprocessing markets.
Key financial metrics
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Total revenue | $50.2 million | $46.9 million | Up 7% |
| Product and service revenue | $49.9 million | $44.5 million | Up 12% |
| Gross profit / margin | $25.3 million / 50% | $26.0 million / 56% | Down $0.7 million; margin contracted |
| Operating expenses | $68.1 million | $61.4 million | Up $6.7 million |
| Operating loss | $42.8 million | $35.4 million | Loss widened $7.4 million |
| Net loss | $36.4 million; $1.13 per share | $33.6 million; $1.07 per share | Loss widened $2.8 million |
| Cash used in operations | $25.1 million | $20.9 million | Outflow increased $4.1 million |
Interest income rose to $6.5 million from $2.0 million, substantially offsetting the larger operating loss. Recurring consumables and service revenue was $16.5 million, 33% of product and service revenue, compared with 35% in FY2022. Product and service gross margin was pressured by higher warranty-related materials, inventory obsolescence provisions, intangible amortization and service delivery costs.
At December 31, 2023, cash and cash equivalents were $121.0 million and marketable securities were $24.6 million, for combined reported balances of $145.7 million. Current assets were $173.8 million and current liabilities $22.5 million. No debt was outstanding; the company repaid $15.0 million under its revolver in January 2023. Operating cash use, investing cash use and financing cash use were $25.1 million, $26.4 million and $15.9 million, respectively. The company reported a $170.6 million accumulated deficit.
Material changes and operating developments
- Handheld revenue increased to $37.9 million from $29.5 million, driven by MX908 and AVCAD-related activity. Desktop revenue fell to $12.0 million from $14.9 million, chiefly due to fewer Rebel and ZipChip placements; new Maven and Maverick shipments partly offset the decline.
- Product placements were 402 handheld units versus 370 and 66 desktop units versus 80. Cumulative placements reached 2,422 handheld and 431 desktop devices at year-end.
- Government product and service revenue rose to $37.9 million from $30.0 million; pharmaceutical/biotechnology revenue declined to $11.3 million from $14.2 million. One customer accounted for 21% of total revenue in 2023, compared with 28% in 2022.
- Research and development expense increased 25% to $21.9 million; selling, general and administrative expense increased 5% to $46.2 million. Stock-based compensation was $9.8 million, up from $7.2 million.
- The company launched Maven in January 2023 and Maverick in September 2023, expanding its bioprocess monitoring and control offerings. Trace Analytics, acquired in 2022, contributed sampling technology and German operations.
Outlook, risks and unusual items
Management expects continued losses as it invests in sales, manufacturing, research and development, and commercialization. It states that cash, cash equivalents and marketable securities are expected to fund operating expenses, capital expenditures and debt service for at least 12 months from the March 8, 2024 financial-statement issuance date. No specific revenue or earnings guidance is provided in the supplied filing text.
- Financing and covenant event: Following Silicon Valley Bank’s closure in March 2023, the company transferred substantially all its funds, triggering a covenant default under its revolver. In August 2023, the lender waived specified rights and amended the facility, reducing the commitment from $35 million to $10 million. The amended facility includes a requirement to maintain $20 million on account at or through the lender and a minimum liquidity/cash-burn covenant. No amount was drawn at year-end.
- Demand and concentration: Sales can be lumpy, particularly large government orders, and sales cycles may last six to twelve months or longer. Government budgets, channel partners and a limited number of customers can affect results. Desktop life-sciences adoption remains a growth objective amid declining desktop revenue in 2023.
- Execution and supply: The company cites competition, the need to scale production and sales support, and reliance on single-source suppliers for certain subassemblies and components. Boston production capacity is approximately 2,000 combined annual units for MX908, Rebel, Maverick and ZipChip Interface.
- Other risks: The company has a history of losses and may need additional capital. Macroeconomic uncertainty, customer spending, U.S. government funding, export controls, intellectual-property licenses, cybersecurity and regulatory requirements for products currently marketed for research use only are identified risks.
- Unusual items: FY2023 contract revenue decreased 84% to $0.4 million as government-related contract work concluded. The company recorded a $0.5 million debt-extinguishment loss related to the revolver events and a $0.3 million credit for previously recorded early-termination penalties. Two Trace acquisition earnout milestones were achieved; a further $0.5 million payment was made in February 2024.
The independent auditor issued an unqualified opinion on the consolidated financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal control, consistent with the company’s emerging-growth-company status. No material legal proceedings or cybersecurity incidents with a material effect were reported.
Important facts for investors to verify
- Whether the amended revolver’s $20 million lender-account requirement and cash-burn covenant remain satisfied, and whether the lender relationship or facility terms have changed.
- Whether cash burn moderates sufficiently to support management’s stated 12-month liquidity outlook; compare operating cash outflow and investment spending with subsequent filings.
- Whether desktop placements and revenue recover, and whether new Maven and Maverick products convert into repeat deployments and consumables revenue.
- How much 2023 revenue depended on the largest customer, government programs and channel partners, and whether order timing is affecting comparisons.
- Whether falling gross margin, higher operating expenses, warranty costs and inventory provisions improve as volume and product mix evolve.